\-\ Texto\\:\\ \ \(0\)\
\-\ ace\\ level\\ \\=\\ 105\\ u\\/l\\ \\(normal\\ 9\\-67\\)\ \(0\)\
\-\ normal\\ physical\\ exam\\ with\\ the\\ exception\\ of\\ the\\ rash\\.\ \(0\)\
\-\ the\\ patient\\ is\\ followed\\ on\\ a\\ routine\\ basis\\ by\\ pulmonology\\ but\\ remains\\ asymptomatic\\.\ \(0\)\
\-\ lymphadenopathy\\ and\\ nodular\\ interstitial\\ opacities\\ with\\ an\\ upper\\ lobe\\ predominance\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ sarcoid\ \(163\)\
\-\ silicosis\\ \ \(1\)\
\-\ lymphangitic\\ carcinomatosis\ \(14\)\
\-\ the\\ patient\\ presented\\ to\\ dermatology\\ with\\ a\\ facial\\ rash\\.\\ after\\ a\\ full\\ work\\-up\\,\\ to\\ include\\ biopsies\\,\\ sarcoidosis\\ was\\ diagnosed\\ and\\ the\\ patient\\ was\\ referred\\ to\\ pulmonology\\ for\\ further\\ evaluation\\.\\ the\\ patient\\ was\\ otherwise\\ asymptomatic\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pulmonology\\:\\ 0\\.15098040164639967\ \(0\)\
\-\ rash\\:\\ 0\\.11438682442466536\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.08482838167835688\ \(0\)\
\-\ 9\\-67\\:\\ 0\\.08480116632196032\ \(0\)\
\-\ ace\\:\\ 0\\.06573961626275036\ \(0\)\
\-\ exception\\:\\ 0\\.06511150182494872\ \(0\)\
\-\ silicosis\\:\\ 0\\.06511150182494872\ \(0\)\
\-\ 105\\:\\ 0\\.063953693960577\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.06348554720870522\ \(0\)\
\-\ lymphangitic\\:\\ 0\\.06241784843997087\ \(0\)\
\-\ biopsies\\:\\ 0\\.06065584129628758\ \(0\)\
\-\ \\-\\:\\ 0\\.060386652484891105\ \(0\)\
\-\ predominance\\:\\ 0\\.05878881891392057\ \(0\)\
\-\ carcinomatosis\\:\\ 0\\.057494499840773504\ \(0\)\
\-\ u\\/l\\:\\ 0\\.05719341221233268\ \(0\)\
\-\ basis\\:\\ 0\\.05633669197640178\ \(0\)\
\-\ work\\-up\\:\\ 0\\.053038839312112354\ \(0\)\
\-\ dermatology\\:\\ 0\\.05066841543489597\ \(0\)\
\-\ \\=\\:\\ 0\\.04928335256791393\ \(0\)\
\-\ opacities\\:\\ 0\\.04899790766238359\ \(0\)\
\-\ remains\\:\\ 0\\.04885791836812612\ \(0\)\
\-\ sarcoid\\:\\ 0\\.048183534342013015\ \(0\)\
\-\ interstitial\\:\\ 0\\.04594274105205344\ \(0\)\
\-\ facial\\:\\ 0\\.04083134061694835\ \(0\)\
\-\ full\\:\\ 0\\.040566532357837796\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.03993115245796059\ \(0\)\
\-\ nodular\\:\\ 0\\.039389118759471556\ \(0\)\
\-\ routine\\:\\ 0\\.0376532603752747\ \(0\)\
\-\ patient\\:\\ 0\\.03765239256775332\ \(0\)\
\-\ referred\\:\\ 0\\.03543441146654551\ \(0\)\
\-\ diagnosed\\:\\ 0\\.034529617107637425\ \(0\)\
\-\ otherwise\\:\\ 0\\.03372873882886094\ \(0\)\
\-\ was\\:\\ 0\\.03258057765539627\ \(0\)\
\-\ followed\\:\\ 0\\.03148215243273375\ \(0\)\
\-\ further\\:\\ 0\\.029862023536266574\ \(0\)\
\-\ normal\\:\\ 0\\.029442031969211014\ \(0\)\
\-\ evaluation\\:\\ 0\\.027277349404690197\ \(0\)\
\-\ level\\:\\ 0\\.027064714589526726\ \(0\)\
\-\ include\\:\\ 0\\.026342346022310847\ \(0\)\
\-\ presented\\:\\ 0\\.025597336648597906\ \(0\)\
\-\ lobe\\:\\ 0\\.025267311515643234\ \(0\)\
\-\ physical\\:\\ 0\\.023038519445947675\ \(0\)\
\-\ upper\\:\\ 0\\.02266022533372218\ \(0\)\
\-\ exam\\:\\ 0\\.02062894439504987\ \(0\)\
\-\ but\\:\\ 0\\.02002750880256635\ \(0\)\
\-\ after\\:\\ 0\\.01942858464405717\ \(0\)\
\-\ by\\:\\ 0\\.01563594399170192\ \(0\)\
\-\ to\\:\\ 0\\.014079168410208339\ \(0\)\
\-\ a\\:\\ 0\\.01307471874127257\ \(0\)\
\-\ an\\:\\ 0\\.012985328178953075\ \(0\)\
\-\ the\\:\\ 0\\.009115337452986316\ \(0\)\
\-\ for\\:\\ 0\\.008012177457612254\ \(0\)\
\-\ on\\:\\ 0\\.00795484628972998\ \(0\)\
\-\ \\(\\:\\ 0\\.007938040947734731\ \(0\)\
\-\ \\)\\:\\ 0\\.00784107353970665\ \(0\)\
\-\ is\\:\\ 0\\.006179019542689293\ \(0\)\
\-\ \\,\\:\\ 0\\.005949671769610712\ \(0\)\
\-\ and\\:\\ 0\\.003956241884224582\ \(0\)\
\-\ with\\:\\ 0\\.0038572805304359255\ \(0\)\
\-\ \\.\\:\\ 0\\.002340628753671183\ \(0\)\
\-\ of\\:\\ 0\\.001280261547230642\ \(0\)\
